Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C41H50N8O8 |
Molar mass | 782.899 g·mol−1 |
|
Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C.[1] It is a pan-genotypic inhibitor of HCV nonstructural protein 5A.[2]
In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.[2]